Cytek BioSciences, Inc. (CTKB) News
Filter CTKB News Items
CTKB News Results
|Loading, please wait...|
CTKB News Highlights
- CTKB's 30 day story count now stands at 7.
- Over the past 22 days, the trend for CTKB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CTKB are NOV and BEAT.
Latest CTKB News From Around the Web
Below are the latest news stories about CYTEK BIOSCIENCES INC that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
In the realm of stock market movements, insider trading activity is often a significant indicator for investors.
FREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, New York. Cytek management is scheduled to participate in a fireside chat on Tuesday, November 28th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good day and thank you for standing by. Welcome to the Cytek Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker […]
Organic Growth Amidst Macro Challenges; Full-Year Revenue Outlook Adjusted
BioTech Breakthrough Awards As the only cell sorter on the market that offers the unique ability to combine the advantages of Full Spectrum Profiling™ technology with high-performance cell sorting, the Cytek® Aurora™ CS system has been selected as the winner of the “Cell Sorting Product of the Year” award in the third annual BioTech Breakthrough Awards program. FREMONT, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, an
FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Total revenue was $48.0 million, representing 19% growth over the third quarter of 2022 Total revenue on a non-GAAP constant currency basis was $47.7 millionOrganic revenue was $41.2 million, representing an increase of 2% compared t
Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FREMONT, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on th
On October 9, 2023, Wenbin Jiang, President and CEO of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company.
Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United StatesFREMONT, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has received EN ISO 13485:2016 Quality Management System (QMS) certification. The certification applies to Cytek’s headquarters and manufacturing operations in Fremont, California for t